Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | PHGDH | O43175 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17960094 | 0.82 | HDAC6 (0.57) | HDAC6HDAC8HDAC1HDAC3PIK3CA | |
| SCHEMBL17960512 | 0.81 | HDAC6 (0.71) | HDAC6HDAC8HDAC1HDAC3 | |
| SCHEMBL17973609 | 0.81 | HDAC6 (0.63) | HDAC6HDAC8HDAC1HDAC3GRM5 | |
| SCHEMBL17960232 | 0.78 | HDAC6 (0.47) | HDAC6HDAC8HDAC1HDAC3PIK3CA | |
| SCHEMBL17960436 | 0.78 | HDAC6 (0.48) | HDAC6HDAC8HDAC1HDAC3 | |
| SCHEMBL17973610 | 0.78 | HDAC6 (0.46) | HDAC6HDAC8HDAC1HDAC3PIK3CA | |
| SCHEMBL17957521 | 0.77 | HDAC6 (0.46) | HDAC6HDAC8HDAC1HDAC3 | |
| SCHEMBL17957583 | 0.77 | HDAC6 (0.46) | HDAC6HDAC8HDAC1HDAC3DRD2 | |
| SCHEMBL17958024 | 0.76 | HPGD (0.49) | HDAC6HDAC8HDAC1HDAC3 | |
| SCHEMBL17960295 | 0.76 | HDAC6 (0.51) | HDAC6HDAC8HDAC1HDAC3PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016126725-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-08-11 | — | — | WO | claimed |
| US-20160222028-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2016-08-04 | — | — | US | claimed |
| US-11891365-B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | VALO HEALTH, INC. (US) | 2024-02-06 | — | — | US | disclosed |
| US-20220363651-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2022-11-17 | — | — | US | disclosed |
| US-10988450-B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-10464909-B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-10464910-B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-10457652-B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-10442776-B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-10421732-B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-09-24 | — | — | US | disclosed |
| US-20190127339-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2019-05-02 | — | — | US | disclosed |
| US-20190119229-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2019-04-25 | — | — | US | disclosed |
| US-20190119228-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2019-04-25 | — | — | US | disclosed |
| US-20190119227-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2019-04-25 | — | — | US | disclosed |
| US-20190119230-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2019-04-25 | — | — | US | disclosed |
| WO-2016126725-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-08-11 | — | — | WO | disclosed |
| US-20160222028-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2016-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119228-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | HDAC6 6/4885HDAC8 9/4885HDAC1 1/4885 |
| US-11891365-B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC4, HDAC2 | HDAC6 6/4885HDAC8 9/4885HDAC1 1/4885 |
| US-10442776-B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC4, HDAC2 | HDAC6 6/4885HDAC8 9/4885HDAC1 1/4885 |
| US-10464910-B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC4, HDAC2 | HDAC6 6/4885HDAC8 9/4885HDAC1 1/4885 |
| US-10457652-B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC4, HDAC2 | HDAC6 6/4885HDAC8 9/4885HDAC1 1/4885 |
| US-20190119227-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | HDAC6 6/4885HDAC8 9/4885HDAC1 1/4885 |
| US-20190127339-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | HDAC6 6/4885HDAC8 9/4885HDAC1 1/4885 |
| US-20190119229-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | HDAC6 6/4885HDAC8 9/4885HDAC1 1/4885 |
| US-20190119230-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | HDAC6 6/4885HDAC8 9/4885HDAC1 1/4885 |
| US-10464909-B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC4, HDAC2 | HDAC6 6/4885HDAC8 9/4885HDAC1 1/4885 |
| US-10988450-B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC4, HDAC2 | HDAC6 6/4885HDAC8 9/4885HDAC1 1/4885 |
| US-20160222028-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | HDAC6 6/4885HDAC8 9/4885HDAC1 1/4885 |
| US-20220363651-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | HDAC6 6/4885HDAC8 9/4885HDAC1 1/4885 |
| US-10421732-B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC4, HDAC2 | HDAC6 6/4885HDAC8 9/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.